X0306 4 2015-06-30 0 0001510580 Kite Pharma, Inc. KITE 0001198321 CHAMPSI FARAH C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404 1 0 0 0 Common Stock 2015-06-30 4 S 0 191798 61.22 D 2234261 I See Footnote Common Stock 2015-06-30 4 S 0 113047 62.14 D 2121214 I See Footnote Common Stock 2015-06-30 4 S 0 358757 63.01 D 1762457 I See Footnote Common Stock 2015-06-30 4 S 0 500 63.82 D 1761957 I See Footnote Common Stock 19666 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.70 to $61.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Reflects the disposition by Alta Partners VIII, L.P. ("APVIII") of 500,000 shares of the Issuer's common stock in a pro-rata distribution to its limited partners on June 30, 2015. The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.71 to $62.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.715 to $63.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Includes 19,666 shares received in a pro-rata distribution from APVIII. In prior reports, the reporting person reported beneficial ownership of all shares of the Issuer's common stock held by APVIII. /s/ David Tanen, Attorney-in-Fact 2015-07-02